Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ophthotech Raises $36 million, In-licenses Aptamers

This article was originally published in Start Up

Executive Summary

Three venture capital firms funded the ophthalmology start-up with a $36 million Series A that will pay for the acquisition of two IND-stage drug candidates: the similarity to another start-up, Lux Biosciences, is startling. Can the founders of Eyetech take the Lux model and build another success for SVLS, HBM Bioventures, and Novo AS?
Advertisement

Related Content

Venture Eyes Ophthalmology--And Likes What It Sees
Ophthotech Corp.
Ophthotech Corp.
Archemix Reduces Aperture to Pursue Orphan Diseases
The A-List: 2007's Trend Shaping Series A Financings
The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs
Lux Biosciences Inc.
Lux Biosciences Inc.
OSI Buys Eyetech, Market Rubs Eyes
OSI Buys Eyetech, Market Rubs Eyes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091459

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel